| Kinase regulation of human MHC class I molecule expression on cancer cells EJ Brea, CY Oh, E Manchado, S Budhu, RS Gejman, G Mo, P Mondello, ... Cancer immunology research 4 (11), 936-947, 2016 | 158 | 2016 |
| Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma P Mondello, S Tadros, M Teater, L Fontan, AY Chang, N Jain, H Yang, ... Cancer discovery 10 (3), 440-459, 2020 | 117 | 2020 |
| Pim kinases in hematological malignancies: where are we now and where are we going? P Mondello, S Cuzzocrea, M Mian Journal of hematology & oncology 7, 1-9, 2014 | 94 | 2014 |
| Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options P Mondello, M Mian, C Aloisi, F Famà, S Mondello, V Pitini Nutrition and cancer 67 (1), 12-26, 2015 | 85 | 2015 |
| Glutamine treatment attenuates the development of ischaemia/reperfusion injury of the gut S Mondello, M Galuppo, E Mazzon, I Domenico, P Mondello, A Carmela, ... European journal of pharmacology 643 (2-3), 304-315, 2010 | 77 | 2010 |
| Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study M Offidani, L Corvatta, L Maracci, AM Liberati, S Ballanti, I Attolico, ... Blood cancer journal 3 (11), e162-e162, 2013 | 73 | 2013 |
| Emerging markers of cachexia predict survival in cancer patients P Mondello, A Lacquaniti, S Mondello, D Bolignano, V Pitini, C Aloisi, ... BMC cancer 14, 1-10, 2014 | 63 | 2014 |
| Palmitoylethanolamide reduces early renal dysfunction and injury caused by experimental ischemia and reperfusion in mice R Di Paola, D Impellizzeri, P Mondello, E Velardi, C Aloisi, A Cappellani, ... Shock 38 (4), 356-366, 2012 | 60 | 2012 |
| Response to dasatinib in a patient with SQCC of the lung harboring a discoid-receptor-2 and synchronous chronic myelogenous leukemia V Pitini, C Arrigo, C Di Mirto, P Mondello, G Altavilla Lung Cancer 82 (1), 171-172, 2013 | 59 | 2013 |
| Frontline treatment of diffuse large B‐cell lymphoma: Beyond R‐CHOP P Mondello, M Mian Hematological oncology 37 (4), 333-344, 2019 | 56 | 2019 |
| Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma P Mondello, E Derenzini, Z Asgari, J Philip, EJ Brea, V Seshan, ... Oncotarget 8 (8), 14017, 2017 | 55 | 2017 |
| Complications of trauma patients admitted to the ICU in level I academic trauma centers in the United States S Mondello, A Cantrell, D Italiano, V Fodale, P Mondello, D Ang BioMed research international 2014, 2014 | 55 | 2014 |
| Protective effect of apocynin, a NADPH-oxidase inhibitor, against contrast-induced nephropathy in the diabetic rats: a comparison with n-acetylcysteine A Ahmad, S Mondello, R Di Paola, E Mazzon, E Esposito, MA Catania, ... European Journal of Pharmacology 674 (2-3), 397-406, 2012 | 52 | 2012 |
| Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation A Lacquaniti, G Altavilla, A Picone, V Donato, V Chirico, P Mondello, ... Clinical and experimental medicine 15, 97-105, 2015 | 48 | 2015 |
| NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death Y Liu, P Mondello, T Erazo, NB Tannan, Z Asgari, E de Stanchina, ... Proceedings of the National Academy of Sciences 115 (47), 12034-12039, 2018 | 46 | 2018 |
| Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations P Mondello, EJ Brea, E De Stanchina, E Toska, AY Chang, M Fennell, ... JCI insight 2 (6), 2017 | 46 | 2017 |
| Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse S Bobillo, E Joffe, D Sermer, P Mondello, P Ghione, PC Caron, ... Blood cancer journal 11 (6), 113, 2021 | 45 | 2021 |
| Lenalidomide in relapsed or refractory diffuse large B-cell lymphoma: is it a valid treatment option? P Mondello, N Steiner, W Willenbacher, S Ferrero, P Ghione, A Marabese, ... The oncologist 21 (9), 1107-1112, 2016 | 44 | 2016 |
| 90 Y-ibritumomab tiuxetan: a nearly forgotten opportunity P Mondello, S Cuzzocrea, M Navarra, M Mian Oncotarget 7 (7), 7597, 2016 | 44 | 2016 |
| Bendamustine plus Rituximab versus R‐CHOP as first‐line treatment for patients with Follicular Lymphoma grade 3A: evidence from a multicenter, retrospective study P Mondello, N Steiner, W Willenbacher, C Cerchione, D Nappi, E Mauro, ... The oncologist 23 (4), 454-460, 2018 | 42 | 2018 |
